Thiopurines in Crohn's disease, is there something new?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 12, 2010, Pages 1505-1514

  Miheller, Pal ^a   Lakatos, Peter Laszlo ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Azathioprine; Crohn's disease; Inflammatory bowel disease; Pharmacology; TMPT

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; FUROSEMIDE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL PAIN; ADD ON THERAPY; ALLERGIC REACTION; BONE MARROW SUPPRESSION; CANCER RISK; CROHN DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FEVER; FLU LIKE SYNDROME; GENETIC VARIABILITY; HUMAN; LIVER INJURY; LIVER TOXICITY; MALAISE; NAUSEA; PANCREATITIS; PATHOGENESIS; RASH; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AZATHIOPRINE; CROHN DISEASE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES;

EID: 78649284173     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.525505     Document Type: Review

References (74)

1. Mundy CF-LM. The emergence of new biologic treatment options for Crohn's disease and ulcerative colitis: physician and payer attitudes. Available from: http://decisionresourcescom/Productsand-Services/Report?r=pforxx0108 2008
2. Elion GB. The purine path to chemotherapy. Science 1989;244(4900):41-7
3. Marathias VM, Sawicki MJ, Bolton PH. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res 1999;27(14):2860-7
4. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40(10):723-51
5. Brunton L, Blumenthal D, Buxton I, et al. Goodman and Gilman's manual of pharmacology and therapeutics. McGraw and Hills; 2006
6. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000;14(8):1009-14
7. Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61(15):5810-6
8. Haglund S, Taipalensuu J, Peterson C, et al. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 2008;65(1):69-77
9. Vikingsson S, Carlsson B, Almer SH, et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther Drug Monit 2009;31(3):345-50
10. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010. [Epub ahead of print]
11. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130(4):1047-53
12. Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008;103(12):3115-22
13. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5(2):209-14
14. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986;35(20):3533-41
15. Quemeneur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 2003;170(10):4986-95
16. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111(8):1133-45
17. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006;176(1):640-51
18. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005;312(2):537-45
19. Dignass A, Van Assche GLJ, Lemann M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62
20. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302(18):981-7 (Pubitemid 10125406)
21. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7737):1273-6
22. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7731):944-7
23. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69
24. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8
25. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105(2):367-72
26. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66(5):916-22
27. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD000545
28. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;4: CD000545
29. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975;20(8):721-6
30. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;2(8097):955-7 (Pubitemid 9061740)
31. Saibeni S, Virgilio T, D'Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis 2008;40(10):814-20
32. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617-25
33. de Boer NK, Derijks LJ, Gilissen LP, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005;11(35):5540-4
34. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115(4):813-21
35. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006;101(12):2769-76
36. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103(7):1783-800
37. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14(7):407-17
38. Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14, 545 patients. Dig Dis Sci 2007;52(5):1262-9
39. Pettersson B, Almer S, Albertioni F, et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002;24(3):351-8
40. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39(4):456-9
41. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62(4):464-75
42. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102(12):2747-53
43. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53(8):1123-8
44. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16(1):79-85
45. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 1991;50(6):663-72
46. de Boer NK, van Bodegraven AA, de Graaf P, et al. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit 2008;30(3):390-3
47. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583(1):83-90
48. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423:169-78
49. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51(2):143-6
50. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-30
51. Roberts RL, Gearry RB, Barclay ML, et al. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007;7(5):312-17
52. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006;24(8):767-81
53. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5): V1-16
54. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl 1986;548:87-99
55. Dubinsky I. "The Future of Emergency Medicine" Inaugural address to the First Canadian EM Residents Workshop. CJEM 2000;2(4):262-4
56. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50(4):485-9
57. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12(6):429-36
58. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102(7):1518-27 (Pubitemid 46976279)
59. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005;37(4):282-97
60. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004;99(9):1744-8
61. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29(6):654-61
62. Bermejo F, Lopez-Sanroman A, Algaba A, et al. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31(1):120-4
63. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56(10):1404-9 (Pubitemid 47517834)
64. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43(2):303-9
65. Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004;28(9):1204-11
66. de Boer NK, Zondervan PE, Gilissen LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis 2008;40(2):108-13
67. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989;111(8):641-9
68. de Jong DJ, Derijks LJ, Naber AH, et al. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003;38(Suppl 239):69-72
69. Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999;28(4):341-4
70. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14(3):181-7
71. Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004;14(11):779-81
72. van Geenen EJ, de Boer NK, Stassen P, et al. Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon. Aliment Pharmacol Ther 2010;31(12):1322-29
73. Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med 1983;309(15):900-10
74. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117(3):527-35